The Claim
In overweight or obese adults with type 2 diabetes, baseline visfatin levels are negatively correlated with fasting plasma glucose levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In overweight or obese adults with type 2 diabetes, higher levels of visfatin in the blood at the start of treatment are linked to lower fasting blood glucose levels.
See the scientific wording
In overweight or obese adults with type 2 diabetes, baseline visfatin levels are negatively correlated with fasting plasma glucose, suggesting that higher visfatin may be associated with better glucose control at the start of treatment.
Higher levels of visfatin increase how well fat and muscle cells respond to insulin, allowing them to take up more glucose from the blood, which lowers fasting blood sugar levels.
What the research says
1 studyEven though the study gave people a diabetes drug, it also checked their blood sugar and visfatin levels before starting the drug — and found that people with higher visfatin tended to have lower blood sugar right from the start.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.